Article
Presentation 7: Where Does HEOR Fit in the Oncology Model?
Author(s):
According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.
According to Dr Ramsey, both the Health Economics Outcomes Research (HEOR) model and the pharmaceuticals pricing model in the United States are broken. He says: “Unless we, as a community, figure out a way to use health economics in our decision making, we are not going to stop this train of unsupportable price increases in pharma.”
HEOR is defined as a multidisciplinary approach that is aimed at estimating value. This value usually includes costs and outcomes, as well as factors such as looking at the budget impact of new technologies, patient-reported outcomes, practice patterns, comparative effectiveness, and cost- effectiveness.
Dr Ramsey argues that unless we look at value and cost, the outcomes and research have little meaning. We cannot make good decisions and improve value for patients until cost and quality are taken into account.
“I think we need to put the H-E back into HEOR and figure out ways, as a community, for using that as a leverage point for breaking the current price trend in oncology,” he says.
